Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 5260976, 13 pages
https://doi.org/10.1155/2018/5260976
Research Article

Cyclodextrin Enhances Corneal Tolerability and Reduces Ocular Toxicity Caused by Diclofenac

1Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Mina, Egypt
2Department of Ophthalmology, Faculty of Medicine, Minia University, Minia, Egypt
3Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Mina, Egypt
4School of Science and Technology, Nottingham Trent University, 50 Shakespeare Street, Nottingham NG1 4FQ, UK

Correspondence should be addressed to Barbara Pierscionek; ku.ca.utn@kenoicsreip.arabrab

Received 22 July 2017; Revised 1 October 2017; Accepted 17 December 2017; Published 13 February 2018

Academic Editor: Kai Kaarniranta

Copyright © 2018 Hamdy Abdelkader et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Loftsson and M. Masson, “Cyclodextrins in topical drug formulations: theory and practice,” International Journal of Pharmaceutics, vol. 225, no. 1-2, pp. 15–30, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Mai, E. L.-M. MA, O. Y. Abdallah, and H. Abdelkader, “Reduction of bitterness and enhancing palatability of cetirizine oral liquid dosage forms by cyclodextrins,” Journal of Pharmaceutics & Drug Development, vol. 1, no. 3, pp. 1–8, 2014. View at Publisher · View at Google Scholar
  3. C. D. Radu, O. Parteni, and L. Ochiuz, “Applications of cyclodextrins in medical textiles-review,” Journal of Controlled Release, vol. 224, pp. 146–157, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Scavone, A. C. Bonagura, S. Fiorentino et al., “Efficacy and safety profile of diclofenac/cyclodextrin and progesterone/cyclodextrin formulations: a review of the literature data,” Drugs in R&D., vol. 16, no. 2, pp. 129–140, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Irie and K. Uekama, “Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation,” Journal of Pharmaceutical Sciences, vol. 86, no. 2, pp. 147–162, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Loftsson and E. Stefánsson, “Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye,” Acta Ophthalmologica Scandinavica, vol. 80, no. 2, pp. 144–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. H. H. Sigurdsson, E. Stefánsson, E. Gudmundsdóttir, T. Eysteinsson, M. Thorsteinsdóttir, and T. Loftsson, “Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration,” Journal of Controlled Release, vol. 102, no. 1, pp. 255–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. EMA, Background Review for Cyclodextrins Used as Excipients, pp. 1–17, 2014.
  9. P. W. Morrison, C. J. Connon, and V. Khutoryanskiy, “Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability,” Molecular Pharmaceutics, vol. 10, no. 2, pp. 756–762, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Loftsson and T. Jarvinen, “Cyclodextrins in ophthalmic drug delivery,” Advanced Drug Delivery Reviews, vol. 36, no. 1, pp. 59–79, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Ohtani, T. Irie, K. Uekama, K. Fukunaga, and J. Pitha, “Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes,” European Journal of Biochemistry, vol. 186, no. 1-2, pp. 17–22, 1989. View at Publisher · View at Google Scholar · View at Scopus
  12. A. C. Guidera, J. I. Luchs, and I. J. Udell, “Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs,” Ophthalmology, vol. 108, no. 5, pp. 936–944, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Ahuja, A. S. Dhake, S. K. Sharma, and D. K. Majumdar, “Topical ocular delivery of NSAIDs,” The AAPS Journal, vol. 10, no. 2, pp. 229–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. J. Kim, A. J. Flach, and L. M. Jampol, “Nonsteroidal anti-inflammatory drugs in ophthalmology,” Survey of Ophthalmology, vol. 55, no. 2, pp. 108–133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. N. G. Congdon, O. D. Schein, P. von Kulajta, L. H. Lubomski, D. Gilbert, and J. Katz, “Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs,” Journal of Cataract and Refractive Surgery, vol. 27, no. 4, pp. 622–631, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. J. Flach, “Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs,” Transactions of the American Ophthalmological Society, vol. 99, pp. 205–210, 2001. View at Google Scholar
  17. A. Fernandez-Ferreiro, M. Santiago-Varela, M. Gil-Martínez et al., “Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention,” International Journal of Pharmaceutics, vol. 495, no. 2, pp. 680–691, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Reer, T. K. Bock, and B. W. Müller, “In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product voltaren ophtha,” Journal of Pharmaceutical Sciences, vol. 83, no. 9, pp. 1345–1349, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Feng, R. Fawaz, S. Hovde, F. Sheng, M. Nosrati, and J. H. Geiger, “Crystal structures of Escherichia coli branching enzyme in complex with cyclodextrins,” Acta Crystallographica Section D Structural Biology, vol. 72, no. 5, pp. 641–647, 2016. View at Publisher · View at Google Scholar
  20. S. Shityakov, R. E. Salmas, S. Durdagi et al., “Characterization, in vivo evaluation, and molecular modeling of different propofol-cyclodextrin complexes to assess their drug delivery potential at the blood-brain barrier level,” Journal of Chemical Information and Modeling, vol. 56, no. 10, pp. 1914–1922, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Llinàs, J. C. Burley, K. J. Box, R. C. Glen, and J. M. Goodman, “Diclofenac solubility: independent determination of the intrinsic solubility of three crystal forms,” Journal of Medicinal Chemistry, vol. 50, no. 5, pp. 979–983, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Abdelkader, M. R. Longman, R. G. Alany, and B. Pierscionek, “Phytosome-hyaluronic acid systems for ocular delivery of L-carnosine,” International Journal of Nanomedicine, vol. 11, pp. 2815–2827, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. R. D. Schoenwald and H. S. Huang, “Corneal penetration behavior of β-blocking agents I: physichochemical factors,” Journal of Pharmaceutical Sciences, vol. 72, no. 11, pp. 1266–1272, 1983. View at Publisher · View at Google Scholar · View at Scopus
  24. R. W. Lewis, Red Blood Cell (RBC)Llysis and Protein Denaturation DB-ALM Protocol No 99, EURL ECVAM DB-ALM, 2010.
  25. P. J. Weterings and Y. H. Vanerp, Eds.A. M. Goldberg, Ed., Validation of the Becam Assay: An Eye Irritancy Screening Test, in Alternative Methods in Toxicology, Mary Ann Liebert, Inc, New York, 1987.
  26. H. Abdelkader, S. Ismail, A. Hussein, Z. Wu, R. al-Kassas, and R. G. Alany, “Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen’s egg chorioallantoic membrane and excised bovine cornea models,” International Journal of Pharmaceutics, vol. 432, no. 1-2, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Abdelkader, O. Y. Abdallah, and H. Salem, “Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide,” AAPS PharmSciTech, vol. 8, no. 3, pp. E110–E117, 2007. View at Publisher · View at Google Scholar
  28. M. Saravanan, K. Bhaskar, G. Maharajan, and K. S. Pillai, “Development of gelatin microspheres loaded with diclofenac sodium for intra-articular administration,” Journal of Drug Targeting, vol. 19, no. 2, pp. 96–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Bratu, A. Hernanz, J. M. Gavira, and G. H. Bora, “FT-IR spectroscopy of inclusion complexes of β-cyclodextrin with fenbufen and ibuprofen,” Romanian Journal of Physics, vol. 50, pp. 1063–1071, 2005. View at Google Scholar
  30. J. Li, Q. Jiang, P. Deng et al., “The formation of a host-guest inclusion complex system between β-cyclodextrin and baicalin and its dissolution characteristics,” The Journal of Pharmacy and Pharmacology, vol. 69, no. 6, pp. 663–674, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Sallmann, Chemical Aspects of Diclofenac, in Chronic Forms of Polyarthritis, F. J. Wagenhäuser, Ed., International Symposium, Torremolinos, Hans Huber Berne, 1975.
  32. M. R. Caira, V. J. Griffith, L. R. Nassimbeni, and B. van Oudtshoorn, “Synthesis and X-ray crystal structure of β-cyclodextrin diclofenac sodiu undecahydrate, a β-CD complex with a unique crystal packing arrangement,” Journal of the Chemical Society, Chemical Communications, vol. 9, no. 9, pp. 1061-1062, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Attwood, “The mode of association of amphiphilic drugs in aquoes solution,” Advances in Colloid and Interface Science, vol. 55, pp. 271–303, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Mucci, L. Schenetti, M. A. Vandelli, B. Ruozi, and F. Forni, “Evidence of the existence of 2:1 guest-host complexes between diclofenac and cyclodextrins in D2O solutions. A 1H and 13C NMR study on diclofenac/β-cyclodextrin and diclofenac/2-hydroxypropyl-β-cyclodextrin,” Journal of Chemical Research, vol. S, pp. 414-415, 1999. View at Publisher · View at Google Scholar
  35. B. Pose-Vilarnovo et al., “Interaction of diclofena sodium with β and hydroxypropyl-β-cyclodextrin in solution,” STP Pharma Sciences, vol. 9, pp. 231–236, 1999. View at Google Scholar
  36. R. Valls, E. Vega, M. L. Garcia, M. A. Egea, and J. O. Valls, “Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drugs in drug delivery systems,” The Open Medicinal Chemistry Journal, vol. 2, no. 1, pp. 66–71, 2008. View at Publisher · View at Google Scholar
  37. H. Abdelkader, S. Ismail, A. Kamal, and R. G. Alany, “Design and evaluation of controlled release niosomes and discomes for naltrexone hydrochloride ocular delivery,” Journal of Pharmaceutical Sciences, vol. 100, no. 5, pp. 1833–1846, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. E. N. Alves, F. Presgrave Rde, O. A. Presgrave, F. P. Sabagh, J. C. de Freitas, and A. P. Corrado, “A reassessment of the in vitro RBC haemolysis assay with defibrinated sheep blood for the determination of the ocular irritation potential of cosmetic products: comparison with the in vivo draize rabbit test,” Alternatives to Laboratory Animals, vol. 36, no. 3, pp. 275–284, 2008. View at Google Scholar
  39. W. J. Pape and U. Hoppe, “Standardization of an in vitro red blood cell test for evaluating the acute cytotoxic potential of tensides,” Arzneimittelforschung, vol. 40, no. 4, pp. 498–502, 1990. View at Google Scholar
  40. K. Jarvinen, T. Jarvinen, and A. Urtti, “Ocular absorption following topical delivery,” Advanced Drug Delivery Reviews, vol. 16, no. 1, pp. 3–19, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Gautheron, M. Dukic, D. Alix, and J. F. Sina, “Bovine corneal opacity and permeability test: an in vitro assay of ocular irritancy,” Fundamental and Applied Toxicology, vol. 18, no. 3, pp. 442–449, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Grover and K. Jamil, “Alternatives methods for dermal and ocular animal safety testing of chemicals,” Proceedings-Indian National Science Academy Part A, vol. B67, pp. 1–20, 2001. View at Google Scholar
  43. C. K. Muir, “Opacity of bovine cornea in vitro induced by surfactants and industrial chemicals compared with ocular irritancy in vivo,” Toxicology Letters, vol. 24, no. 2-3, pp. 157–162, 1985. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Ayaki, A. Iwasawa, and Y. Inoue, “Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells,” Clinical Ophthalmology, vol. 4, pp. 1217–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Eleftheriadis, M. Cheong, S. Sandeman et al., “Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery,” The British Journal of Ophthalmology, vol. 86, no. 3, pp. 299–305, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Mencucci, D. E. Pellegrini-Giampietro, I. Paladini, E. Favuzza, U. Menchini, and T. Scartabelli, “Azithromycin: assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures,” Clinical Ophthalmology, vol. 7, pp. 965–971, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Ghoreishi, H. Attarzadeh, M. Tavakoli et al., “Alcohol-assisted versus mechanical epithelium removal in photorefractive keratectomy,” Journal of. Ophthalmic& Vision Research., vol. 5, no. 4, pp. 223–227, 2010. View at Google Scholar
  48. J. C. Abad, B. An, W. J. Power, C. S. Foster, D. T. Azar, and J. H. Talamo, “A prospective evaluation of alcohol-assisted versus mechanical epithelial removal before photorefractive keratectomy,” Ophthalmology, vol. 104, no. 10, pp. 1566–1575, 1997. View at Publisher · View at Google Scholar